In vitro inhibition effect of some coumarin compounds on purified human serum paraoxonase 1 (PON1)

References

• Aharoni A, Gaidukov L, Khersonsky O, et al. The ‘evolvability’ of promiscuous protein functions. Nat Genet 2005;37:73–6
   PubMed Web of Science ®Google Scholar
• Alici HA, Ekinci D, Beydemir S. Intravenous anesthetics inhibit human paraoxonase-I (PON1) activity in vitro and in vivo. Clin Biochem 2008;41:1384–90
   PubMed Web of Science ®Google Scholar
• Khersonsky O, Tawfik DS. Structure–reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005;44:6371–82
   PubMed Web of Science ®Google Scholar
• Rochua D, Chabriere E, Massona P. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning. Toxicology 2007;233:47–59
   PubMed Web of Science ®Google Scholar
• Akgur SA, Ozturk P, Solak I, Moral AR. Human serum paraoxonase (PON1) activity in acute organophosphorus insecticide poisoning. Forensic Sci Int 2003;133:136–40
   PubMed Web of Science ®Google Scholar
• Natala SR, Muralidhar RM, Stephan C, et al. Synthesis of new coumarin 3-(N-aryl)sulfonamides and their anticancer activities. Bioorg Med Chem Lett 2004;14:4093–7
   PubMed Web of Science ®Google Scholar
• Markus G. Synthesis and structure–activity relationships of novel warfarin derivatives. Bioorg Med Chem 2007;15:2414–20
   PubMed Web of Science ®Google Scholar
• Donglei Y, Madoka S, Lan X, et al. Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med Res Rev 2003;3:322–45
   Google Scholar
• Gurram RM, Vodla B, Bejugam M, et al. Novel coumarin derivatives of heterocyclic compounds as lipid lowering agents. Bioorg Med Chem Lett 2003;13:2547–51
   PubMed Web of Science ®Google Scholar
• Christos AK, Dimitro JH. Synthesis and antiinflammatory activity of coumarin derivatives. J Med Chem 2005;48:6400–8
   PubMed Web of Science ®Google Scholar
• Smyth T, Ramochandran VN, Smyth WF. A study of the antimicrobial activity of selected naturally occurring and synthetic coumarins. Int J Antimicrob Agents 2009;33:421–6
   PubMed Web of Science ®Google Scholar
• Zahid HC, Ali V, Shaikh A, Supuran CT. Antibacterial, antifungal and cytotoxic properties of novel N-substituted sulfonamides from 4-hydroxy coumarin. J Enzyme Inhibit Med Chem 2006;16:741–8
   Google Scholar
• Kameli MA, Abdelrahman D, Yasmin AA. Synthesis and preliminary evaluation of some substituted coumarins as anticonvulsant agents. Bioorg Med Chem Lett 2008;16:5377–88
   Web of Science ®Google Scholar
• Hougland RR. Handbook of fluorescent probes and research products. 9th ed. Eugene: Moleculer Probes; 2002
   Google Scholar
• Reddy NS, Mallireddigari MR, Cosenza S, et al. Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. Bioorg Med Chem Lett 2004;14:4093–7
   PubMed Web of Science ®Google Scholar
• Finn GJ, Creaven BS, Egan DA. A study of the role of cell cycle events mediating the action of coumarin derivatives in human malignant melanoma cells. Cancer Lett 2004;214:43–54
   PubMed Web of Science ®Google Scholar
• Alfonso M, Claudia T, Hoan V, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–62
   PubMed Web of Science ®Google Scholar
• Erzengin M, Basaran I, Cakir U, et al. In vitro inhibition effect of some dihydroxy coumarin compounds on purified human serum paraoxonase 1 (PON1). Appl Biochem Biotechnol 2012;168:1540–8
   PubMed Web of Science ®Google Scholar
• Karatas MO, Alici B, Cakir U, et al. Synthesis and carbonic anhydrase inhibitory properties of novel coumarin derivatives. J Enzyme Inhib Med Chem 2012;28:299–304
   PubMed Web of Science ®Google Scholar
• Karatas MO, Alici B, Cakir U, et al. New coumarin derivatives as carbonic anhydrase inhibitors. Artif Cells Nanomed Biotechnol 2014;42:192–8
   PubMed Web of Science ®Google Scholar
• Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100–6
   PubMed Web of Science ®Google Scholar
• Sinan S, Kockar F, Arslan O. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. Biochimie 2006;88:565–74
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quotation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–54
   PubMed Web of Science ®Google Scholar
• Laemmli DK. Cleavage of structural proteins during in assembly of the head of bacteriohhoge T4. Nature 1970;227:680–5
   PubMed Web of Science ®Google Scholar
• Sinan S, Kockar F, Gencer N, et al. Amphenicol and macrolide derived antibiotics inhibit paraoxonase enzyme activity in human serum and human hepatoma cells (HepG2) in vitro. Biochemistry (Moscow) 2006;71:46–50
   PubMed Web of Science ®Google Scholar
• Arslan M, Gencer N, Arslan O, Guler OO. In vitro efficacy of some cattle drugs on bovine serum paraoxonase 1 (PON1) activity. J Enzyme Inhib Med Chem 2012;27:722–9
   PubMed Web of Science ®Google Scholar
• Ekinci D, Beydemir S. Effect of some analgesics on paraoxonase-1 purified from human serum. J Enzyme Inhib Med Chem 2009;24:1034–9
   PubMed Web of Science ®Google Scholar
• Sayin D, Cakir DT, Gencer N, Arslan O. Effects of some metals on paraoxonase activity from shark Scyliorhinus canicula. J Enzyme Inhib Med Chem 2012;27:595–8
   PubMed Web of Science ®Google Scholar
• Gencer N, Ergun A, Demir D. In vitro effects of some anabolic compounds on erythrocyte carbonic anhydrase I and II. J Enzyme Inhib Med Chem 2012;27:208–10
   PubMed Web of Science ®Google Scholar
• Billecke S, Draganov D, Counsell R, et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000;28:1335–41
   PubMed Web of Science ®Google Scholar
• Billecke S, Draganov D, Counsell R, et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000;28:1335–42
   PubMed Web of Science ®Google Scholar
• Egan D, O'Kennedy R, Moran E, et al. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev 1990;22:503–29
   PubMed Web of Science ®Google Scholar
• Lake BG. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem Toxicol 1999;37:423–53
   PubMed Web of Science ®Google Scholar
• Felter SP, Vassallo JD, Carlton BD, Daston GP. A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food Chem Toxicol 2006;44:462–75
   PubMed Web of Science ®Google Scholar
• Cox D, O’Kennedy R, Thornes RD. The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum Toxicol 1989;8:501–6
   PubMedGoogle Scholar
• Burian M, Freudenstein J, Tegtmeier M, et al. Single copy of variant CYP2A6 alleles does not confer susceptibility to liver dysfunction in patients treated with coumarin. Int J Clin Pharmacol Ther 2003;41:141–7
   PubMed Web of Science ®Google Scholar
• Vanscheidt W, Rabe E, Naser-Hijazi B, et al. The efficacy and safety of a coumarin-/troxerutincombination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomised study. Vasa 2002;31:185–90
   PubMed Web of Science ®Google Scholar